Compare BioNTech SE - ADR (BNTX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Lumen Technologies Inc — how do they compare? BioNTech SE - ADR trades at $90.48 (market cap $22.86B), while Lumen Technologies Inc trades at $6.49 (market cap $6.56B). The key difference: BioNTech SE - ADR is far larger — about 3.5× Lumen Technologies Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | LUMN | |
|---|---|---|
Market Cap | $22.86B | $6.56B |
Sector | Health | Media |
52-Week High | $119.34 | $11.83 |
52-Week Low | $83.89 | $3.70 |
Enterprise Value | $6.53B | $18.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
LUMN trades at $6.45, down 4.16% today, reflecting ongoing investor caution amid a bearish technical signal. The company reported a net loss of $1.74 billion in 2025 despite beating earnings expectations in two of the last three quarters. Recent news highlights strategic moves like the Alkira acquisition to bolster its AI networking platform. Cash flow from operations remains strong at $4.74 billion, but high debt levels and negative profitability metrics pose challenges.
The outlook is mixed; cost-cutting and a $13 billion contract backlog offer potential upside, but persistent losses and a heavy debt load of $17.49 billion limit near-term growth. Analyst consensus is cautious with a hold-heavy rating, though the $8.25 price target implies modest upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
